ArriVent BioPharma News

ArriVent BioPharma Analyst Ratings

BenzingaJun 6 06:14 ET

Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements

TipRanksMay 20 08:31 ET

ArriVent BioPharma Analyst Ratings

BenzingaMay 9 07:19 ET

Buy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical Trials

TipRanksMay 9 06:41 ET

Buy Rating Affirmed for ArriVent BioPharma on Strong Firmonernib Prospects and Financial Stability

TipRanksMay 8 16:00 ET

ArriVent BioPharma Analyst Ratings

BenzingaApr 30 06:14 ET

Jefferies Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)

TipRanksApr 11 08:02 ET

Buy Rating on ArriVent BioPharma Highlighting Furmonertinib's Potential in NSCLC Treatment Landscape

TipRanksApr 1 06:01 ET

Furmonertinib's Market Potential in NSCLC: A Buy Rating for ArriVent BioPharma

TipRanksMar 27 16:50 ET

Buy Rating on ArriVent BioPharma: Advancing NSCLC Treatment With Promising Furmonertinib Prospects

TipRanksMar 4 08:02 ET

LifeSci Capital Starts ArriVent BioPharma With Outperform Rating, $33 Price Target

MT NewswiresFeb 20 12:10 ET

Strong Buy Rating for ArriVent BioPharma Amidst Unmet NSCLC Treatment Needs

TipRanksFeb 20 07:25 ET

Citi Starts ArriVent Stock With Buy Rating Citing Promising Lung Cancer Drug

InvestingFeb 20 06:46 ET

ArriVent BioPharma Analyst Ratings

BenzingaFeb 20 05:45 ET

Analysts Are Bullish on Top NA Stocks: BrightSpring Health Services, Inc. (BTSG), ArriVent BioPharma, Inc. (AVBP)

TipRanksFeb 20 04:40 ET

ArriVent BioPharma Stock Gets Buy Rating From Jefferies, Highlights Near Term Data

InvestingFeb 20 04:30 ET